D-Risk Investing Podcast

Can a stock surge 1,700% in a single day and still be a sell? On this episode of D-Risk, we dissect Wolfspeed (WOLF), the semiconductor company that just completed a court-approved corporate rebirth, shedding 70% of its debt and releasing a new product. But this phoenix is flying into a storm: a stunning 50%+ short interest and half of Wall Street analysts flashing 'Strong Sell' are battling a technical chart that looks like a volcanic eruption. Tune in as we cut through the noise of yesterday's massive short squeeze to establish the critical price levels that determine if this move is a sustainable recovery or an overbought rally destined to crash back to earth.

Is this rental giant a dirt-cheap bargain, or a financial breakdown waiting to happen? On this episode of D-Risk, we crash-test Hertz (HTZ), a stock where one fundamental model suggests a value over $90, yet another screams zero. While the company secures major financing, every Wall Street analyst says 'Hold' or 'Sell,' and the stock is caught in a dramatic civil war: hyper-bullish options traders are battling a colossal 43% short-interest. Tune in as we dissect the extreme polarization in this stock's story and pinpoint the critical $7.00 and $6.00 levels that will determine its next explosive move.

Is Etsy's massive AI partnership a revolutionary leap, or a classic case of speculative hype? On this episode of D-Risk, we dive deep into ETSY, where a game-changing deal with ChatGPT is running headlong into a valuation gap you could drive a truck through. While technical charts scream "Buy" and options traders are overwhelmingly bullish, a staggering 28% short interest creates a powder keg, and a discounted cash flow model suggests the stock is profoundly overvalued. Tune in as we weigh the explosive technical momentum against alarming fundamental risks to deliver a strategic outlook on whether the AI-powered future can truly justify today's sky-high price.

Lockheed Martin ($LMT) is a defense powerhouse swimming in a $20 billion contract boom, but is the stock flying too high? While technicals show a forceful rally and strong institutional buying, our valuation models suggest the price is trading at a significant premium to its fair value. We reveal the split between skeptical Wall Street analysts, who overwhelmingly rate it a "Hold," and options traders who are bracing for volatility. Tune in to D-Risk as we break down this overbought chart to find the key price level, a floor defended by millions in options bets, that will determine if this aerospace giant is cleared for a continued ascent or if it's due for a dramatic, profit-taking correction.

Bristol-Myers Squibb ($BMY) is facing a classic "value trap" dilemma: cash flow models scream a fair price near $97 a share, yet the stock trades around $44. We dive into the massive disconnect fueled by deep R&D cuts and a bearish technical trend, which has 73% of Wall Street analysts stuck on the sidelines with a "Hold" rating. But don't look away, bullish options traders are placing heavy bets on a reversal from oversold territory. Tune in to D-Risk as we break down the conflicting signals to reveal the key price level that will determine if this pharma giant is a bargain bin treasure or a falling knife that's about to bounce.

Ford ($F) just unveiled a massive new EV plan, promising a game-changing $30,000 electric truck by 2027, but Wall Street's "Hold" rating suggests analysts aren't ready to shift gears. Dive into this fascinating disconnect as we reveal why multiple valuation models scream "undervalued," dissect a strongly bullish options market, and break down the technical breakout that has the stock accelerating. Will the prospect of affordable EVs finally light a fire under this classic automaker? Tune in to D-Risk to find out which key price level bulls must conquer to put the skepticism in the rearview mirror!

Is Wolfspeed (WOLF) a phoenix rising from the ashes of bankruptcy or a dying star heading for a black hole? This episode of D-Risk dives into the high-stakes drama of the silicon carbide semiconductor specialist, whose stock just plummeted over 20% pre-market despite a recent court approval of its debt-slashing reorganization plan. The fundamentals are a chaotic mess, with analyst "fair value" estimates swinging from a lofty $29 to a negative valuation, and a jaw-dropping 51% of the available shares sold short. We strip away the noise to dissect the technical carnage, analyzing the decisive breakdown below key support and the overwhelming bearish conviction from professional skeptics, to determine if this flash crash is a final capitulation or the violent start of a potential, face-ripping short squeeze that could ignite on any flicker of good news.

Is the scorching rally in Centrus Energy (LEU) a rocket ship riding the nuclear renaissance or a volatile roman candle set to fizzle? The stock is white-hot following a bombshell multi-billion-dollar expansion plan for its U.S. uranium enrichment plant, perfectly timed for a global market where uranium prices are soaring and demand is forecast to jump 28% by 2030. However, the stock closed yesterday at $312, a staggering premium to its $189 fair value, igniting a fierce battle between giddy options bulls and a massive crowd of short-sellers who have piled into a whopping 20.67% of the float. With the technical trend screaming bullish, yet flashing "overextended," we cut through the noise to dissect this high-stakes tension between fundamental transformation, extreme valuation, and the growing risk of an explosive short squeeze.

Is Datavault AI's $150 million Bitcoin-funded supercomputer strategy a game-changer, or is its money-losing past too heavy a burden? This episode of D-Risk dives into the high-stakes battle over ticker DVLT, where the market is cheering a spectacular, forward-looking catalyst while the company's intrinsic worth still whispers a mere $0.33 per share. With short-sellers betting against the stock's explosive breakout and technical indicators flashing "overbought," we analyze whether a powerful short squeeze is about to ignite or if fundamental gravity will pull the price back to earth. Join us for a no-nonsense analysis of DVLT's technical trends, valuation disconnect, and market sentiment.

AI darling Astera Labs (ALAB) was one of the market's highest flyers, but what happens when giants like Intel and Nvidia threaten to step on its turf? A sudden 10% plunge has turned this stock into a major battleground, pitting bullish Wall Street analysts against a starkly bearish reality: its cash-flow valuation is a mere $17, yet it trades for over $200. With the technical charts confirming a violent, high-volume breakdown and short-sellers smelling blood, the central question is urgent. In this episode, we dissect the data to determine if this is a golden buying opportunity or the beginning of a catastrophic collapse for a massively overvalued company.

What happens when a biotech company announces a potential miracle cure and, mere hours later, hands the market a $100 million bill? That's the complex diagnosis facing PepGen (PEPG) after a bombshell clinical trial announcement sent its stock exploding upwards on stampede-like volume, only to be followed by a massive, dilutive share offering. With a significant number of traders betting against it and a chart screaming both "breakout" and "dangerously overbought," the stock is now a major battleground. In this episode, we dissect the conflict between groundbreaking science and financial reality to determine if this explosive rally has a healthy prognosis or if it's just a flash of market fever destined to fade.